{"product_id":"tirzepatide-30mg","title":"TIRZEPATIDE 30mg","description":"\u003cp\u003eTirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-2\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its ~5‑day half‑life allows convenient\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eonce‑weekly subcutaneous\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003edosing\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-3\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-4\"\u003e[4]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitute:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eAdd\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e3.0 mL\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ebacteriostatic water →\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e10.0 mg\/mL\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003econcentration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical weekly range:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e2.5–15 mg\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eonce weekly (gradual 4‑week titration steps).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEasy measuring:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eAt 10.0 mg\/mL,\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e1 unit = 0.01 mL = 100 mcg\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eon a U‑100 insulin syringe.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eLyophilized: freeze at\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e−20 °C (−4 °F)\u003c\/strong\u003e; after reconstitution, refrigerate at\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e2–8 °C (35.6–46.4 °F)\u003c\/strong\u003e; use within 28 days.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cimg\u003e\u003c\/p\u003e\n\u003cdiv class=\"table-responsive\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eWeekly Dose (mg)\u003c\/th\u003e\n\u003cth\u003eUnits (per injection) (mL)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 1–4\u003c\/td\u003e\n\u003ctd\u003e2.5 mg\u003c\/td\u003e\n\u003ctd\u003e25 units (0.25 mL) × 1 injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd\u003e5 mg\u003c\/td\u003e\n\u003ctd\u003e50 units (0.50 mL) × 1 injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003e75 units (0.75 mL) × 1 injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 13–16\u003c\/td\u003e\n\u003ctd\u003e10 mg\u003c\/td\u003e\n\u003ctd\u003e100 units (1.0 mL) × 1 injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003eFrequency:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eInject\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eonce weekly\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003esubcutaneously on the same day each week\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-5\"\u003e[5]\u003c\/a\u003e\u003c\/sup\u003e. All doses fit in a single 1 mL insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003cspan\u003e \u003c\/span\u003e\u003cem\u003eHigher doses (12.5–15 mg\/week) may be used in subsequent phases if tolerated and clinically indicated.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cimg\u003e\u003c\/p\u003e","brand":"USA Peptides","offers":[{"title":"Default Title","offer_id":47177206956281,"sku":null,"price":0.0,"currency_code":"PYG","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0790\/5394\/7129\/files\/Tirzepatide30mgmlfrente.png?v=1767699696","url":"https:\/\/zenithlabsusa.com\/products\/tirzepatide-30mg","provider":"USA Peptides","version":"1.0","type":"link"}